Anti-tumour activity of low-toxicity lipopolysaccharide of Bordetella pertussis

Br J Cancer. 1994 Jun;69(6):1038-42. doi: 10.1038/bjc.1994.204.


A lipopolysaccharide (BP-LPS) isolated from killed Bordetella pertussis (Tohama strain) was determined to have low toxicity based on the mortality and decrease in body weight of BP-LPS-injected mice. BP-LPS, administered intradermally or intraperitoneally, clearly inhibited the growth of an MM46 murine mammary carcinoma. When compared with a toxic Escherichia coli-derived LPS, BP-LPS displayed excellent anti-tumour activity against MH134 hepatoma and Meth A fibrosarcoma. As part of a combined chemotherapy/immunotherapy regimen, BP-LPS also seemed to prolong the lifespan of mice inoculated with Lewis lung carcinoma. BP-LPS thus appears to have valuable characteristics as an anti-tumour agent.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Antineoplastic Agents / isolation & purification
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Agents / toxicity*
  • Body Weight / drug effects
  • Bordetella pertussis*
  • Cell Line
  • Cyclophosphamide / therapeutic use
  • Drug Screening Assays, Antitumor
  • Escherichia coli
  • Fibrosarcoma / drug therapy
  • Gram-Negative Bacteria
  • Lentinan / therapeutic use
  • Lethal Dose 50
  • Lipopolysaccharides / isolation & purification
  • Lipopolysaccharides / therapeutic use*
  • Lipopolysaccharides / toxicity*
  • Liver Neoplasms, Experimental / drug therapy
  • Lung Neoplasms / drug therapy
  • Male
  • Mammary Neoplasms, Experimental / drug therapy
  • Mice
  • Mice, Inbred C3H
  • Mice, Inbred C57BL
  • Mice, Inbred ICR
  • Neoplasms, Experimental / drug therapy*
  • Tumor Cells, Cultured


  • Antineoplastic Agents
  • Lipopolysaccharides
  • Lentinan
  • Cyclophosphamide